JAMP-METOPROLOL-L 100 MG
METOPROLOL TARTRATE : 100 MG · DIN 02356848 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP-METOPROLOL-L?
JAMP-METOPROLOL-L 100 MG contains METOPROLOL TARTRATE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02356848, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 04-May-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-METOPROLOL-L used for?
Mild or moderate hypertension; long-term treatment of angina pectoris; treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce mortality.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02356848 |
|---|---|
| Brand name | JAMP-METOPROLOL-L |
| Generic / active ingredient | METOPROLOL TARTRATE : 100 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB02 METOPROLOL |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-May-2018 |
| Original market date | 2010-10-21 00:00:00 |
How is it administered?
Hypertension: Usually combined with a diuretic. Myocardial Infarction: Oral treatment can begin within 3 to 10 days of the acute event. Dosage must be individualized.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section 11, but text ends at Drug Interactions).
How is it supplied?
Not explicitly detailed in provided text (mentions 25mg, 50mg, 100mg strengths).
Contraindications
Hypersensitivity to metoprolol; sinus bradycardia; sick sinus syndrome; 2nd/3rd degree A-V block; right ventricular failure; overt heart failure; cardiogenic shock; severe peripheral arterial disorders.
Warnings and precautions
Avoid abrupt withdrawal. Use with caution in patients with heart failure, bronchospastic diseases, diabetes (may mask hypoglycemia), and peripheral vascular disease.
Is METOPROLOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C07AB02 METOPROLOL. 30 of 103 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-METOPROLOL SR | 100 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02285169 |
| APO-METOPROLOL | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00618640 |
| APO-METOPROLOL | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02246010 |
| APO-METOPROLOL | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00618632 |
| APO-METOPROLOL (TYPE L) | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00751170 |
| APO-METOPROLOL (TYPE L) | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00749354 |
| JAMP-METOPROLOL-L | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02356813 |
| JAMP-METOPROLOL-L | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02356821 |
| METOPROLOL | 100 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02350408 |
| METOPROLOL | 50 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02350394 |
Who else supplies METOPROLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METOPROLOL appears in 449 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.